Likelihood of Approval Analysis for Fatty Acid Biosynthesis Disorders
Powered by
Unlock hidden opportunities in the LoA industry
Overview
How likely is it that the drugs in Fatty Acid Biosynthesis Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.
Fatty Acid Biosynthesis Disorders Overview
Fatty acid biosynthesis disorders (FABDs) are a group of inherited metabolic disorders that affect the ability of the body to use fatty acids as a source of energy. Fatty acids are long chains of carbon and hydrogen atoms that are stored in fat cells and can be broken down to produce energy when glucose (sugar) is not available. However, people with FABDs have defects in the enzymes or transport proteins that are involved in the process of fatty acid breakdown, also called fatty acid oxidation. This leads to a buildup of fatty acids or their byproducts in the blood and tissues, and a shortage of energy for the cells. FABDs can cause various symptoms depending on the type and severity of the disorder, such as low blood sugar, muscle weakness, heart problems, liver enlargement, brain damage, and developmental delays. FABDs are diagnosed by newborn screening tests, genetic tests, or biochemical tests that measure the levels of fatty acids or their metabolites in the blood or urine. Treatment of FABDs depends on the specific disorder, but usually involves dietary modifications, supplements, medications, and avoiding fasting or prolonged exercise. FABDs are rare disorders that affect about 1 in 10,000 to 50,000 people worldwide.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for industry benchmarks and drug comparisons.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
Quick View – Fatty Acid Biosynthesis Disorders LOA Data | |||||
Report Segments |
|
||||
Drug Name |
|
||||
Administration Pathway |
|
||||
Therapeutic Areas |
|
Reasons to Buy
- Predict the specific likelihood of approval and phase transition success rates of a drug using a combination of machine learning and proprietary models
- Get information on LOA and PTSR for competitors’ drugs to plan your clinical development, commercialization and marketing strategies
- Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR
- Use PTSR and LOA information and event-driven changes for your investment decisions.
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Frequently asked questions
- Drugs which have been approved in the past 10 years
- Drugs which have failed during clinical development in the past 18 years
- Drugs which are currently in development
- Phase I, Phase II, Phase III, and Pre-Registration development stage
- Drugs must meet one of the following criteria to be included in the model:
- The developer has specified the US as an intended market for approval.
- The developer has not specified any country as an intended market for approval, i.e. the “Drug Geography” is listed as “Global”
- Innovator drugs and biosimilars
- Diagnostics, Imaging Agents, Biomarkers, stents and other drug delivery devices (covered in GlobalData’s Medical Intelligence Center).
- Nutraceuticals, dietary supplements, alternative medicines, imaging agents, radio emitter, transplants, transfusions, fillers, cosmetics, probiotics, antiseptics, antacids, mobilizing agents, veterinary drugs and drugs not seeking approval.
- Generic drugs
- Innovative drugs in Preclinical or Discovery Stage.
- Pipeline drugs sponsored by a Government or Institution.
- Drugs with a specific Drug Geography not the United States.
The probability of a drug ultimately receiving market authorization
The probability of a drug’s advancement to the next stage of clinical development
GlobalData’s Drug-Specific Likelihood of Approval (LoA) calculates the Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) customized to individual drug. The model uses a combination of Machine Learning (ML) and a GlobalData proprietary algorithm to process data points from the Drugs, Clinical Trials, Regulatory Milestones, Company, and Financial databases.
Inclusion
Data Scope:
Drug Phase Scope:
Drug Geography Scope:
Drug Type Scope:
Entity Type Scope:
Only drugs in development by companies are included in the model.
Exclusion
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745